Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male patient with histologically confirmed prostate cancer (adenocarcinoma).~* Patient in whom endocrine treatment is indicated. Patient having undergoing prostatectomy or radiotherapy with curative intention and has a rising serum PSA (PSA ≥ 2 ng/mL at screening) may be included.~* Has a serum testosterone level above 2.2 ng/mL at screening.~* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2 at screening.~* Has a serum PSA ≥ 2 ng/mL at screening.~* Has a life expectancy of at least 12 months.~Exclusion Criteria:~* Previous or present endocrine treatment for prostate cancer. Example: surgical castration, GnRH agonists, GnRH antagonists, antiandrogens or oestrogens, and 5α-reductase inhibitors.~* Received a 5α-reductase inhibitor within 25 weeks preceding screening.~* Is a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within 12 months.~* Has concurrent or a history of poorly controlled severe asthma, anaphylactic reactions, severe urticaria or angioedema.~* Has hypersensitivity towards mannitol.~* Has a marked prolongation of QT/QTc interval (two consecutive increases to \>450 ms in QTc interval at retest) at screening.~* Has concurrent or a history of a disease (heart failure, hypokalemia, a family history of QT prolongation syndrome, etc.) that may induce Torsade de Pointes.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASP3550 PART 1 and PART 2 (Type: EXPERIMENTAL): Part 1 for 1 year treatment and Part 2 for an extended period of treatment
- Goserelin (Type: ACTIVE_COMPARATOR): part 1 for 1 year treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).